- Home
- AMBO vs GNPX Comparison
AMBO vs GNPX Comparison
Compare AMBO & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBO
- GNPX
- Stock Information
- Founded
- AMBO 2000
- GNPX 2009
- Country
- AMBO United States
- GNPX United States
- Employees
- AMBO N/A
- GNPX N/A
- Industry
- AMBO Other Consumer Services
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- AMBO Real Estate
- GNPX Health Care
- Exchange
- AMBO Nasdaq
- GNPX Nasdaq
- Market Cap
- AMBO 7.2M
- GNPX 6.1M
- IPO Year
- AMBO 2010
- GNPX 2018
- Fundamental
- Price
- AMBO $2.65
- GNPX $0.39
- Analyst Decision
- AMBO
- GNPX Strong Buy
- Analyst Count
- AMBO 0
- GNPX 1
- Target Price
- AMBO N/A
- GNPX $10.00
- AVG Volume (30 Days)
- AMBO 24.5K
- GNPX 1.5M
- Earning Date
- AMBO 12-30-2024
- GNPX 03-31-2025
- Dividend Yield
- AMBO N/A
- GNPX N/A
- EPS Growth
- AMBO N/A
- GNPX N/A
- EPS
- AMBO N/A
- GNPX N/A
- Revenue
- AMBO $7,839,000.00
- GNPX N/A
- Revenue This Year
- AMBO N/A
- GNPX N/A
- Revenue Next Year
- AMBO N/A
- GNPX N/A
- P/E Ratio
- AMBO N/A
- GNPX N/A
- Revenue Growth
- AMBO N/A
- GNPX N/A
- 52 Week Low
- AMBO $1.00
- GNPX $0.28
- 52 Week High
- AMBO $5.55
- GNPX $5.41
- Technical
- Relative Strength Index (RSI)
- AMBO 54.68
- GNPX 23.70
- Support Level
- AMBO $2.34
- GNPX $0.38
- Resistance Level
- AMBO $2.80
- GNPX $0.55
- Average True Range (ATR)
- AMBO 0.31
- GNPX 0.05
- MACD
- AMBO -0.02
- GNPX 0.00
- Stochastic Oscillator
- AMBO 63.82
- GNPX 12.78
About AMBO Ambow Education Holding Ltd.
Ambow Education Holding Ltd is a provider of educational and career enhancement services in China. It operates through CP&CE Programs. The CP&CE Programs include tutoring services and career enhancement services. Geographically all the operations function in the United States and Foreign countries.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.